Enlivex Therapeutics (ENLV) investor relations material

Company overview and business model

• Focuses on quality longevity therapeutics and operates a dual strategy: clinical development and a treasury model anchored in decentralized prediction markets via the RAIN protocol.

• Clinical-stage immunotherapy company developing Allocetra, an off-the-shelf cell therapy targeting inflammatory conditions, with osteoarthritis as the primary indication.

• Treasury operations utilize the RAIN token as the primary reserve asset, providing investor exposure to prediction markets.

• Incorporated in Israel, with principal offices in Ness Ziona and a U.S. subsidiary in Delaware.

Financial performance and metrics

• Raised $21.0 million through a Senior Secured Convertible Promissory Note in a private placement, receiving $19.0 million in proceeds.

• The Note matures March 23, 2027, with nine monthly principal installments of ~$2.3 million each, starting 90 days after closing.

• Note can be repaid in cash, ordinary shares, or a combination, with shares valued at 90% of the five lowest daily VWAPs in the prior 20 trading days.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares; all net proceeds go to the selling shareholder.

• Bears all fees and expenses related to registering the shares for resale.